PE20050985A1 - Formulaciones de inhibidores de la fosfodiesterasa v - Google Patents

Formulaciones de inhibidores de la fosfodiesterasa v

Info

Publication number
PE20050985A1
PE20050985A1 PE2004001130A PE2004001130A PE20050985A1 PE 20050985 A1 PE20050985 A1 PE 20050985A1 PE 2004001130 A PE2004001130 A PE 2004001130A PE 2004001130 A PE2004001130 A PE 2004001130A PE 20050985 A1 PE20050985 A1 PE 20050985A1
Authority
PE
Peru
Prior art keywords
quantities
composition
phosphodiesterase
inhibitors
formulations
Prior art date
Application number
PE2004001130A
Other languages
English (en)
Inventor
Zhiyun Wang
Surendra A Sangekar
Ping I Lee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34632926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050985(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20050985A1 publication Critical patent/PE20050985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
    • B05D7/14—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2202/00—Metallic substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2258/00—Small objects (e.g. screws)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE CONSTA DE UNA DISPERSION DE ALTA ENERGIA SUSTANCIALMENTE AMORFA QUE COMPRENDE (A) UN INGREDIENTE ACTIVO TAL COMO 7-[(3-BROMO-4-METOXIFENIL)METIL]-1-ETIL-3,7-DIHIDRO-8-[[(1R,2R)-2-HIDROXICICLOPENTIL]AMINO]-3-(2-HIDROXIETIL)-1H-PURIN-2,6-DIONA EN CANTIDADES DE 25, 50 Y 100 mg, (B) UNA MATRIZ POLIMERICA QUE A SU VEZ COMPRENDE EN RELACION DE 1:1 A 1:10 (a) UN VEHICULO POLIMERICO COMO POVIDONA DE PESOS MOLECULARES DE 3000 A 1.000.000 EN CANTIDADES DE 30 A 90% EN LA COMPOSICION Y (b) UNA BASE HUMECTANTE TAL COMO POLISORBATO 80 Y PLURONIC F-68 EN CANTIDADES DE 0,5% A 3% Y DE 3% A 10%, RESPECTIVAMENTE. LA COMPOSICION COMPRENDE ADEMAS UN DESINTEGRANTE COMO CROSCARAMELOSA SODICA Y CROSPOVIDONA, UN LUBRICANTE COMO ESTEARATO DE MAGNESIO Y ACIDO ESTEARICO Y UN DILUYENTE COMO CELULOSA MICROCRISTALINA, LACTOSA Y MANITOL. DICHA COMPOSICION ES INHIBIDORA DE LA PDE V UTILES EN EL TRATAMIENTO DE LA DISFUNCION ERECTIL EN EL HOMBRE Y SEXUAL EN LA MUJER, ENTRE OTROS TRANSTORNOS FISIOLOGICOS
PE2004001130A 2003-11-21 2004-11-18 Formulaciones de inhibidores de la fosfodiesterasa v PE20050985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52473103P 2003-11-21 2003-11-21

Publications (1)

Publication Number Publication Date
PE20050985A1 true PE20050985A1 (es) 2005-11-26

Family

ID=34632926

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001130A PE20050985A1 (es) 2003-11-21 2004-11-18 Formulaciones de inhibidores de la fosfodiesterasa v

Country Status (15)

Country Link
US (2) US20060040962A1 (es)
EP (1) EP1691788A2 (es)
JP (1) JP2007512345A (es)
KR (1) KR20060101762A (es)
CN (1) CN1905860A (es)
AR (1) AR047948A1 (es)
AU (1) AU2004292991A1 (es)
BR (1) BRPI0416202A (es)
CA (1) CA2546248A1 (es)
MX (1) MXPA06005681A (es)
NO (1) NO20062883L (es)
PE (1) PE20050985A1 (es)
TW (1) TW200526664A (es)
WO (1) WO2005051368A2 (es)
ZA (1) ZA200604025B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
MX2010005198A (es) * 2007-11-12 2010-05-20 Novartis Ag Composiciones liquidas que comprenden valsartan.
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
JP6002562B2 (ja) * 2012-12-05 2016-10-05 横浜ゴム株式会社 面ファスナー付き空気入りタイヤ及びその製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5470479A (en) * 1994-06-23 1995-11-28 Westinghouse Electric Corporation Continuous, steady-state, chromatographic separation of gadolinium isotopes
UA46166C2 (uk) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
JP3290970B2 (ja) * 1998-07-22 2002-06-10 山之内製薬株式会社 難溶性ＮＳＡＩＤｓ含有固形製剤
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
JP3470096B2 (ja) * 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1421084B1 (en) * 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
AU2002360775B9 (en) * 2001-12-28 2008-07-24 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2003101991A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
JP2005529934A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives

Also Published As

Publication number Publication date
BRPI0416202A (pt) 2006-12-26
WO2005051368A2 (en) 2005-06-09
WO2005051368A3 (en) 2006-03-09
TW200526664A (en) 2005-08-16
CA2546248A1 (en) 2005-06-09
JP2007512345A (ja) 2007-05-17
CN1905860A (zh) 2007-01-31
NO20062883L (no) 2006-08-18
MXPA06005681A (es) 2006-08-17
AR047948A1 (es) 2006-03-15
ZA200604025B (en) 2008-01-30
US20090074869A1 (en) 2009-03-19
EP1691788A2 (en) 2006-08-23
AU2004292991A1 (en) 2005-06-09
KR20060101762A (ko) 2006-09-26
US20060040962A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
CA2360668A1 (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
EP1112075B1 (en) Compositions for the treatment of male erectile dysfunction
PL1802277T3 (pl) Kompozycja liposomowa zawierająca aktywny składnik do rozluźniania mięśni gładkich, otrzymywania tej kompozycji i jej zastosowanie terapeutyczne
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
AR048963A1 (es) Formulaciones de interferon de hidrogel de poloxamero
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
ES2733044T1 (es) Composición farmacéutica que contiene oxicodona y naloxona
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
AR039335A1 (es) Tableta de carga de droga alta
HRP20040479B1 (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
TW200606164A (en) New compounds
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
PE20050985A1 (es) Formulaciones de inhibidores de la fosfodiesterasa v
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
ES2065846B1 (es) Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
CA2521182A1 (en) Composition for improving cognition and memory
RS51615B (en) PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC KERATITIS
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására

Legal Events

Date Code Title Description
FC Refusal